SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS (SCYX) completed its Phase 1 study of intravenous SCY-247, reporting generally favorable tolerability in healthy participants and no drug-related serious adverse events. The study enrolled 56 participants; 42 received SCY-247 and 14 received placebo. Mild to moderate infusion-site redness and pain were the most common adverse reactions, with no discontinuations due to a related adverse event.
Once-daily IV doses of 50 mg or higher achieved exposures at or above a target identified in mouse models of invasive candidiasis, not demonstrated patient efficacy. SCYNEXIS expects Phase 2 development of oral and IV formulations in 2027, subject to FDA agreement. A BARDA cost-share contract provides up to approximately $214 million in non-dilutive funding if milestones are achieved. The company expects its share of near-term costs to fit its existing operating plan; its projected cash runway into 2029 remains unchanged.
SCYNEXIS (SCYX) will feature its antifungal candidate SCY-247 in an oral pipeline presentation at IDWeek on October 23, 2026. President and CEO David Angulo will speak at 8:00 a.m. Eastern time in room 206 at the Walter E. Washington Convention Center in Washington, D.C. SCY-247 is under development in oral and intravenous formulations for treating and preventing invasive fungal infections.
SCYNEXIS (SCYX) completed a Phase 1 study of SCY-770 to support development for autosomal dominant polycystic kidney disease (ADPKD). The oral drug activates AMPK, an enzyme. The study evaluated safety, tolerability and pharmacokinetics—how the body processes the drug—to support Phase 2 dose selection.
The study enrolled 25 healthy participants across three cohorts. The initial cohort received a single 500 mg dose under fed and fasted conditions. Subsequent cohorts received 750 mg once daily, 500 mg twice daily, or placebo for seven days. SCY-770 was well tolerated across all cohorts, with safety consistent with prior clinical experience. Safety and tolerability have been characterized in approximately 300 participants across multiple trials.
SCYNEXIS expects the Phase 2 study in ADPKD patients to begin in the fourth quarter of 2026. SCY-770 has FDA Orphan Drug Designation for ADPKD.
SCYNEXIS (SCYX) secured a BARDA contract offering up to approximately $214 million for development of antifungal candidate SCY-247.
The initial base period provides approximately $18.5 million to support oral and intravenous SCY-247 advancing into a Phase 2 trial for invasive candidiasis. The contract shares costs: BARDA supports eligible direct and general and administrative expenses, while SCYNEXIS expects to fund its share of near-term costs within its existing operating plan.
The contract may extend for up to 10 years. If BARDA exercises all options, it could fund SCY-247 through submission of new drug applications for treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. SCYNEXIS said its previously communicated SCY-770 development milestones and projected cash runway into 2029 remain unchanged.
SCYNEXIS (SCYX) appointed nephrology drug development expert Steven K. Burke, M.D. to its Board of Directors, effective September 18, 2026.
Dr. Burke brings more than 30 years of biopharmaceutical experience, with a focus on chronic kidney disease. Since 2019 he has worked at Akebia Therapeutics and since 2021 has served as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer, overseeing research, toxicology, pharmacology, clinical operations, data management, biostatistics, clinical research, regulatory affairs, drug safety and pharmacovigilance, and medical affairs.
He has held leadership roles in development of Vafseo (vadadustat) for anemia due to chronic kidney disease and supported Auryxia (ferric citrate), and oversees programs including praliciguat and ebribafusp alfa for glomerular diseases. SCYNEXIS’ chairman links his appointment to advancing SCY-770, a recently acquired candidate for Autosomal Dominant Polycystic Kidney Disease that the company plans to move into Phase 2.
SCYNEXIS (SCYX) has appointed Todd Minga, M.D., as Senior Vice President, Research & Development, effective September 14, 2026, to lead its rare disease development programs.
Dr. Minga brings over 20 years of experience in nephrology and biopharmaceutical development, including leadership roles at Akebia Therapeutics, Maze Therapeutics, and IQVIA, and more than 16 years as a board-certified nephrologist. He will help advance SCY-770 for autosomal dominant polycystic kidney disease and support the company’s antifungal program.
In connection with his appointment, he received a stock option for 40,000 shares at an exercise price of $4.60 per share and 5,000 RSUs, with options vesting over four years and RSUs vesting in three equal annual installments, all subject to continued service.
SCYNEXIS (SCYX) appointed Sanjay Subramanian, MBA, as Chief Financial Officer effective September 9, 2026, and announced the concurrent retirement of CFO Ivor Macleod, who will remain through October 9, 2026 to support the transition.
Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience in biotechnology, pharmaceuticals and healthcare, including CFO roles at Inozyme Pharma and Ocugen and finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies and General Motors. He led Inozyme Pharma’s acquisition by BioMarin Pharmaceutical. In connection with his appointment, on September 9, 2026 he received an option to purchase 100,000 SCYNEXIS shares at an exercise price of $4.91 per share, with a ten-year term and four-year vesting schedule, granted under the SCYNEXIS 2015 Inducement Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
SCYNEXIS (Nasdaq: SCYX), a clinical-stage biotechnology company, announced participation in two upcoming investor conferences in New York City. The company will join a fireside chat at the 12th Cantor Global Healthcare Conference on Friday, September 11, 2026, at 9:45 a.m. ET, which will be webcast live with a replay available for 90 days. SCYNEXIS will also take part in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026.
SCYNEXIS (Nasdaq: SCYX) granted an inducement equity award to a new Senior Director effective August 24, 2026, under Nasdaq Listing Rule 5635(c)(4). The grant was made pursuant to the company’s 2015 Inducement Award Plan, as amended, to encourage the employee’s acceptance of employment.
The award consists of stock options to purchase 20,000 shares of common stock at an exercise price of $5.26 per share, equal to the closing trading price on the grant date. The options have a ten-year term, with 25% vesting after one year and the remaining shares vesting in equal monthly installments over the following 36 months, subject to continued service.
SCYNEXIS (NASDAQ: SCYX) reported second quarter 2026 results and a corporate update. License revenue was $0.2 million, while operating expenses totaled $8.0 million, leading to a loss from operations of $7.8 million. Net income for the quarter was $7.4 million, driven largely by $15.2 million in other income, including a $14.2 million fair value gain on warrant liabilities.
R&D expenses declined 46% year over year to $3.9 million. The company ended June 30, 2026 with $71.1 million in cash, cash equivalents and investments, supported by a $36.9 million private placement completed in April; SCYNEXIS expects this to fund operations into 2029. The company initiated a Phase 1 study of SCY-770 for ADPKD with topline data expected in Q3 2026 and plans a Phase 2 proof-of-concept trial in Q4 2026. Dosing was completed in a Phase 1 study of IV antifungal SCY-247, with topline data also expected in Q3 2026. According to SCYNEXIS, a BREXAFEMME relaunch by GSK could trigger up to $146 million in annual net sales milestones plus low- to mid-single-digit net royalties.